Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Pfizer plans to discuss these data with regulatory authorities to initiate regulatory filings for Hympavzi for hemophilia patients with inhibitors. Price Action: PFE stock is trading lower by 0.05 ...

PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.